In the Val-HeFT study (Valsartan Heart Failure Trial), which included 1346 patients with chronic HF, it was concluded that both the Gal3 values measured at baseline and the measurement performed 4 months after inclusion were significantly correlated with hospitalization for HF and all-cause mortality. This evidence concerns the gene LGALS3 and heart failure.